Literature DB >> 1381509

Inhibition of human immunodeficiency virus and growth of infected T cells by the immunosuppressive drugs cyclosporin A and FK 506.

A Karpas1, M Lowdell, S K Jacobson, F Hill.   

Abstract

The effects of the immunosuppressive drugs cyclosporin A and FK 506 were studied on cells chronically infected with human immunodeficiency virus type 1 (HIV-1) as well as on uninfected and newly infected cells. When cells chronically infected with HIV-1 or with HIV-2 were cocultivated with uninfected cells in the presence of cyclosporin A or FK 506 there was a delay in the formation of syncytia and of cytopathic effects. This inhibitory effect was not due to decreased membrane expression of CD4. In addition, there was an approximately 100-fold reduction in the yield of infectious HIV-1 when the infected cells were grown in the presence of these drugs, a finding consistent with other evidence of decreased HIV expression. Both drugs were found to inhibit the growth of chronically infected cells at concentrations that did not inhibit the growth of the uninfected cells. These results, demonstrating that cyclosporin A and FK 506 interfere with HIV production and selectively inhibit the growth of infected cells, suggest that they may be useful in the treatment of this infection and indicate further cellular targets for antiviral agents.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1381509      PMCID: PMC49916          DOI: 10.1073/pnas.89.17.8351

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  27 in total

1.  Outcome of HIV infection in transplant patient on cyclosporin.

Authors:  S K Jacobson; R Y Calne; T G Wreghitt
Journal:  Lancet       Date:  1991-03-30       Impact factor: 79.321

2.  [Functional inhibition by cyclosporin A of the lymphocyte receptor for the AIDS virus (HIV)].

Authors:  D Klatzmann; J P Laporte; A Achour; E Brisson; J Gruest; L Montagnier; J C Gluckman
Journal:  C R Acad Sci III       Date:  1986

3.  Persistent noncytopathic infection of normal human T lymphocytes with AIDS-associated retrovirus.

Authors:  J A Hoxie; B S Haggarty; J L Rackowski; N Pillsbury; J A Levy
Journal:  Science       Date:  1985-09-27       Impact factor: 47.728

4.  Organ transplantation in HIV-positive patients with hemophilia.

Authors:  M V Ragni; F A Bontempo; J H Lewis
Journal:  N Engl J Med       Date:  1990-06-28       Impact factor: 91.245

5.  Isolation of a new human retrovirus from West African patients with AIDS.

Authors:  F Clavel; D Guétard; F Brun-Vézinet; S Chamaret; M A Rey; M O Santos-Ferreira; A G Laurent; C Dauguet; C Katlama; C Rouzioux
Journal:  Science       Date:  1986-07-18       Impact factor: 47.728

6.  Lytic infection by British AIDS virus and development of rapid cell test for antiviral antibodies.

Authors:  A Karpas; W Gillson; P C Bevan; J K Oates
Journal:  Lancet       Date:  1985-09-28       Impact factor: 79.321

7.  Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT).

Authors:  B A Larder; S D Kemp
Journal:  Science       Date:  1989-12-01       Impact factor: 47.728

8.  Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A.

Authors:  W M Flanagan; B Corthésy; R J Bram; G R Crabtree
Journal:  Nature       Date:  1991-08-29       Impact factor: 49.962

9.  Cyclosporine-induced deterioration in patients with AIDS.

Authors:  A Phillips; M A Wainberg; R Coates; M Klein; A Rachlis; S Read; F Shepherd; H Vellend; S Walmsley; P Halloran
Journal:  CMAJ       Date:  1989-06-15       Impact factor: 8.262

10.  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS).

Authors:  F Barré-Sinoussi; J C Chermann; F Rey; M T Nugeyre; S Chamaret; J Gruest; C Dauguet; C Axler-Blin; F Vézinet-Brun; C Rouzioux; W Rozenbaum; L Montagnier
Journal:  Science       Date:  1983-05-20       Impact factor: 47.728

View more
  36 in total

Review 1.  New uses for old drugs in HIV infection: the role of hydroxyurea, cyclosporin and thalidomide.

Authors:  E Ravot; J Lisziewicz; F Lori
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

2.  Nef enhances HIV-1 infectivity via association with the virus assembly complex.

Authors:  Mingli Qi; Christopher Aiken
Journal:  Virology       Date:  2008-01-14       Impact factor: 3.616

Review 3.  Antiviral therapy for human immunodeficiency virus infections.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

4.  The hydrophobic pocket of cyclophilin is the binding site for the human immunodeficiency virus type 1 Gag polyprotein.

Authors:  D Braaten; H Ansari; J Luban
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

Review 5.  Current Strategies for Elimination of HIV-1 Latent Reservoirs Using Chemical Compounds Targeting Host and Viral Factors.

Authors:  Maxime J Jean; Guillaume Fiches; Tsuyoshi Hayashi; Jian Zhu
Journal:  AIDS Res Hum Retroviruses       Date:  2018-12-12       Impact factor: 2.205

6.  Cyclophilin interactions with incoming human immunodeficiency virus type 1 capsids with opposing effects on infectivity in human cells.

Authors:  Theodora Hatziioannou; David Perez-Caballero; Simone Cowan; Paul D Bieniasz
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

7.  Spontaneous mutations in the human immunodeficiency virus type 1 gag gene that affect viral replication in the presence of cyclosporins.

Authors:  C Aberham; S Weber; W Phares
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

8.  Mechanistic independence of Nef and cyclophilin A enhancement of human immunodeficiency virus type 1 infectivity.

Authors:  C Aiken
Journal:  Virology       Date:  1998-08-15       Impact factor: 3.616

9.  Cyclophilin A is required for an early step in the life cycle of human immunodeficiency virus type 1 before the initiation of reverse transcription.

Authors:  D Braaten; E K Franke; J Luban
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

10.  Baboon-to-human liver transplantation.

Authors:  T E Starzl; J Fung; A Tzakis; S Todo; A J Demetris; I R Marino; H Doyle; A Zeevi; V Warty; M Michaels
Journal:  Lancet       Date:  1993-01-09       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.